Therapeutic Polyclonal Antibody Development Services
Although cancer therapeutic antibodies with specific antigens are widely used, the use of therapeutic polyclonal antibodies (pAb) in tumor immunotherapy would be a very promising approach. Alfa Cytology offers therapeutic polyclonal antibody development services to help customers multi-target tumor cells with polyclonal antibodies to minimize escape mutations.
Therapeutic Polyclonal Antibody for Cancer Therapy
Polyclonal antibodies have a wide range of applications in cancer therapy. The use of whole tumor cell lysates to produce polyclonal antibodies is a very promising tumor immunotherapy. Rabbit anti-breast cancer polyclonal antibody in combination with tumor cell lysate effectively reduced and inhibited breast cancer proliferation and induced apoptosis in vitro. In addition, this combination therapy reduced tumor growth in a mouse model of subcutaneous breast cancer.
Fig.1 Polyclonal antibody combined with whole tumor cell lysate enhanced anti-tumor efficacy in vivo. (Rahimmanesh, I., et al., 2023)
Advantages of Therapeutic Polyclonal Antibody
The efficacy of monoclonal antibodies is limited by the presence of resistant variants. In contrast, polyclonal antibodies offer many advantages in cancer therapy.
Multi-target
Coverage
Polyclonal antibodies are able to recognize and bind to multiple targets at the same time, which enables polyclonal antibodies to intervene extensively in the growth, proliferation, and signaling pathways of cancer cells and improve therapeutic efficacy.
Overcoming Tumor
Heterogeneity
Heterogeneity of cancer cells exists, meaning that different tumor cells may differ in the expression of surface markers. Polyclonal antibodies overcome the problem of low expression or absence of specific markers that monoclonal antibodies may encounter.
Reducing the Risk of Drug Resistance
Due to the diversity and multi-target coverage of polyclonal antibodies, it is more difficult for cancer cells to rapidly develop resistance. Even if there is a drug-resistant mutation in the cell against a particular antibody, other antibodies can still continue to intervene on other targets, reducing the risk of drug resistance.
Our Services
The polyclonal antibodies can recognize multiple tumor types and remain free of cross-reactivity with normal cells and tissues. Alfa Cytology offers therapeutic polyclonal antibody development services, which provide a foundation for the further development of tumor-loving polyclonal antibodies.
Choosing The Host Species
We offer a variety of competitively priced program packages for different hosts to meet unique needs, which include but are not limited to the following.
Rabbit
Guinea Pig
Chicken
Goat
Rat
Mouse
Blood Drug Concentration/Immunogenicity Detection
To further support and facilitate preclinical studies of antibody drugs, we also offer immunogenicity or pharmacokinetic (PK) assays. Immunogenicity assays are used to quantify the level of immune response against a targeted therapeutic agent, while pharmacokinetic assays are used to elucidate in vivo drug concentrations and drug clearance. Both assays are key regulatory requirements for subsequent drug development.
One-stop Therapeutic Antibody Development
As a comprehensive CRO, Alfa Cytology provides a one-stop shop for antibody development.
Workflow
Target Identification
Identifying potential target molecules that are involved in the disease pathway through genomics and proteomics.
01
Target Validation
The identified targets are further validated to ensure their relevance and suitability as therapeutic targets.
02
Antibody Generation
Generation of specific anti-cancer antibodies using hybridoma technology, phage display, and transgenic animals.
03
Lead Antibody Selection
Functional assays and engineering techniques are applied to optimize their therapeutic potential.
04
Preclinical Studies
Efficacy, safety, pharmacokinetics, and pharmacodynamics are tested in relevant disease models.
05
Polyclonal antibodies have a wide range of promising applications in cancer therapy, overcoming tumor heterogeneity, increasing therapeutic efficacy, and reducing the development of drug resistance. Alfa Cytology provides clients with development services for therapeutic polyclonal antibodies, as well as subsequent characterization services and in vivo assays for drug discovery and development. Please contact us for more information.
Reference
-
Rahimmanesh, I., et al.; (2023). Enhanced in vivo anti-tumor efficacy of whole tumor lysate in combination with whole tumor cell-specific polyclonal antibody. Research in Pharmaceutical Sciences, 18(2), 138-148.
For research use only.
Related Services
